Phase Id Trial to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Advanced Stage Gastric Carcinoma
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2019
Price : $35 *
At a glance
- Drugs Pyrotinib (Primary) ; SHR 6390 (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
- 12 Mar 2019 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 12 Mar 2019 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
- 12 Mar 2019 Status changed from not yet recruiting to recruiting.